KAS
CPRX

Kemnay Advisory Services’s Catalyst Pharmaceutical CPRX Stock Holding History

Kemnay Advisory Services’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23.5K Sell
951
-3,028
-76% -$72.1K ﹤0.01% 584
2025
Q4 		$92.9K Buy
+3,979
New +$88.6K 0.01% 182

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Kemnay Advisory Services's CPRX Position: Q1 2026 in Review

Kemnay Advisory Services reduced its Catalyst Pharmaceutical (CPRX) stake by 76% in Q1 2026, selling an estimated $72.1K and leaving 951 shares worth $23.5K. The position accounts for ﹤0.01% of the portfolio, ranked #584.

Kemnay Advisory Services first reported a position in CPRX in Q4 2025 and has held it in 2 quarters since. The position peaked at $92.9K in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Kemnay Advisory Services held 951 shares of Catalyst Pharmaceutical worth $23.5K as of Q1 2026.
  • Kemnay Advisory Services sold 3,028 Catalyst Pharmaceutical shares in Q1 2026, an estimated $72.1K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Kemnay Advisory Services's portfolio in Q1 2026, its #584 holding.
  • Kemnay Advisory Services first reported a position in Catalyst Pharmaceutical in Q4 2025 and has held it in 2 quarters since.
  • Kemnay Advisory Services's Catalyst Pharmaceutical position peaked at $92.9K in Q4 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Kemnay Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.